Key terms
About BGNE
BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BGNE news
Yesterday
6:16am ET
BeiGene price target lowered to $161 from $196 at Bernstein
Mar 26
8:57pm ET
BeiGene price target lowered to $161 from $196 at Bernstein
Mar 26
7:50pm ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE) and BeiGene (BGNE)
Mar 20
4:22pm ET
BeiGene Announces Executive Team Reshuffle and Director Pay Revision
Mar 15
12:03pm ET
JPMorgan biotech/pharma analysts hold an analyst/industry conference call
Mar 14
4:28pm ET
BeiGene receives FDA approval for Tevimbra
Mar 14
2:04pm ET
BeiGene gets approval for Tevimbra BLA
Mar 13
8:10am ET
BeiGene announces first doses of Brukinsa administered
Mar 07
5:20pm ET
BeiGene announces FDA accelerated approval of BRUKINSA
Feb 29
10:02am ET
BeiGene announces new efficacy analysis comparing Brukinsa vs. Acalabrutinib
Feb 28
12:10am ET
Analysts Are Bullish on These Healthcare Stocks: Athira Pharma (ATHA), BeiGene (BGNE)
Feb 27
11:45pm ET
Buy Rating Reaffirmed on BeiGene Amid Strong Brukinsa Sales and Strategic Stability
Feb 27
7:41am ET
BeiGene price target lowered to $345 from $350 at Guggenheim
Feb 27
7:25am ET
BeiGene price target raised to $235 from $224 at TD Cowen
Feb 27
7:18am ET
BeiGene Hold Rating Upheld Amid Revenue Growth and Market Challenges
Feb 27
6:19am ET
BeiGene’s Biologics License Application for tevimbra accepted by FDA
Feb 27
2:25am ET
BeiGene: Balancing Robust Zanubrutinib Sales and Financial Challenges – A Hold Rating
Feb 27
1:04am ET
BeiGene, Ltd.’s New Technology Risk – A Cause for Worry?
Feb 26
4:45pm ET
Brukinsa’s Market Dominance and BeiGene’s Promising Pipeline Fuel Buy Rating and New Price Target
Feb 26
7:20am ET
Analysts Are Bullish on Top Healthcare Stocks: BeiGene (BGNE), McKesson (MCK)
Feb 26
6:05am ET
BeiGene reports Q4 EPS ($3.53), consensus ($3.73)
Feb 26
5:12am ET
BeiGene receives CHMP opinion recommending approval of tislelizumab
Feb 19
6:16am ET
BeiGene price target lowered to $163 from $200 at BofA
Feb 19
5:45am ET
BeiGene Hold Rating Maintained Amid Mixed Drug Sales and Revised Financial Risk Profile
Feb 12
8:20am ET
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), BeiGene (BGNE) and Catalent (CTLT)
Feb 06
7:04am ET
BeiGene assumed with an Overweight at JPMorgan
Feb 05
10:51am ET
Biotech Alert: Searches spiking for these stocks today
Feb 02
9:27am ET
BeiGene announces Ontario, Quebec publicly list Brukinsa to treat CLL
Jan 25
7:38am ET
BeiGene price target raised to $224 from $222 at TD Cowen
Jan 25
6:50am ET
Analysts Are Bullish on These Healthcare Stocks: BeiGene (BGNE), Travere Therapeutics (TVTX)
Jan 24
3:00am ET
BeiGene Announces Board Reshuffle and New Director Appointment
No recent news articles are available for BGNE
No recent press releases are available for BGNE
BGNE Financials
Key terms
Ad Feedback
BGNE Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BGNE Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range